The effectiveness of sphenopalatine ganglion blockade in chronic migraine resistant to medical treatment

Creative Commons License

Tepe N., Tertemiz O. F.

Neurology Asia, vol.26, no.4, pp.737-741, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.54029/2021jxn
  • Journal Name: Neurology Asia
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Page Numbers: pp.737-741
  • Keywords: Migraine, sphenopalatine ganglion blockade, numerical rating scale, PATHOPHYSIOLOGY, PAIN
  • Gazi University Affiliated: No

Abstract

© 2021, ASEAN Neurological Association. All rights reserved.Objective: To assess the effectiveness of sphenopalatine ganglion blockade (SPGB) as an alternative treatment for patients with chronic migraine resistant to medical treatment. Methods: In total, 23 patients with chronic migraine resistant to medical treatment underwent 4 sessions of bilateral transnasal SPGB bi-weekly, and the monthly number of headache days, duration, and numerical rating scale (NRS) response results were recorded. Results: Compared with before SPGB, the frequency of migraine attacks per month (23.66 ± 9.8 vs. 10.5 ± 11.9 days), duration of headaches (31.3 ± 16.8 vs. 18.4 ± 9.8 h), and NRS score (9 ± 0.99 vs. 5.1 ± 2.1) all improved significantly (p < 0.05) eight weeks after intervention. Conclusion: Transnasal SPGB is an alternative to conventional therapy because it benefits patients with chronic migraine resistant to medical treatment, is easy to administer, and has few side effects.